AAHH will begin using SafeOp’s EPAD portable neuromonitoring system for the detection of nerve damage during surgical procedures.
SafeOp’s goal is to enable simplified neurological monitoring in a wide array of surgical procedures where more complex and expensive monitoring may not be indicated, cost-effective or feasible.
The EPAD™ system was developed particularly for the rapid detection of Positioning Effect (“PE”). PE is a frequent complication of some surgeries (e.g., orthopedic, general, cardiac, or urological surgery), whereby peripheral nerves may be damaged due to unrecognized extended compression or stretching, or compromise of their blood supply.
Additionally, the EPAD system allows easy-to-use monitoring of the neuromuscular junction to aid in detection of residual paralysis, which may occur when paralyzing agents have not sufficiently worn off at the end of surgery.
EPAD offers real-time feedback, allowing caregivers to adjust the patient’s position in time to avoid nerve injury or intervene when residual paralysis is present.
“SafeOp Surgical is pleased to have Abrazo Arizona Heart Hospital as our first customer in Arizona,” said Gene Cattarina, SafeOp’s president and chief executive officer. “We look forward to supporting and contributing to Abrazo’s commitment to excellence in patient care.”
SafeOp Surgical, Inc. is a Hunt Valley, MD-based medical device company that has developed the FDA-approved EPAD™ system.
The EPAD™ system enables basic neurological monitoring in a wide array of surgical procedures where full monitoring, which requires the continuous presence of a technologist and neurologist, may not be indicated, cost-effective or feasible.
